雷贝拉唑联合莫沙必利治疗反流性食管炎患者对胃肠动力学及炎症因子的影响

The effect of rabeprazole combined with mosapride on gastrointestinal dynamics and inflammatory factors in patients with reflux esophagitis

目的探讨雷贝拉唑联合莫沙必利治疗反流性食管炎(RE)患者对胃肠动力学及炎症因子的影响。方法选取2019年3月至2020年3月于本院进行治疗的105例RE患者作为研究对象,按照随机抽签法分为对照组(n=53)和实验组(n=52)。对照组采用雷贝拉唑治疗,实验组采用雷贝拉唑联合莫沙必利治疗,比较两组临床疗效、治疗前和治疗2个月后的胃肠动力学、炎症因子指标变化情况及不良反应发生情况。结果实验组治疗总有效率为96.15%,高于对照组的79.25%,差异有统计学意义(P<0.05)。治疗2个月后,两组胃泌素(GAS)和胃动素(MTL)水平均低于治疗前,胃半排空时间、胃排空时间均短于治疗前,且实验组GAS、MTL水平均低于对照组,胃半排空时间、胃排空时间均短于对照组,差异有统计学意义(P<0.05)。治疗2个月后,两组白细胞介素-17(IL-17)、白细胞介素-23(IL-23)、肿瘤坏死因子-α(TNF-α)水平均明显低于治疗前,且实验组低于对照组,差异有统计学意义(P<0.05)。实验组不良反应发生率高于对照组,但两组比较差异无统计学意义。结论雷贝拉唑联合莫沙必利治疗RE可有效增强治疗效果,降低患者GAS、MTL水平,加速胃排空进程,降低炎症因子水平,且不会增加不良反应的发生,值得临床推广应用。

Objective To investigate the effects of rabeprazole combined with mosapride on gastrointestinal dynamics and inflammatory factors in patients with reflux esophagitis(RE).Methods 105 patients with RE treated in our hospital from March 2019 to March 2020 were selected as the research subjects,they were divided into control group(n=53)and experimental group(n=52)according to random drawing method.The control group was treated with rabeprazole and the experimental group was treated with rabeprazole and mosapride,the clinical efficacy,changes of gastrointestinal dynamics,inflammatory factors before and 2 months after treatment,and adverse reactions were compared between the two groups.Results The total effective rate of the experimental group was 96.15%,which was higher than 79.25%of the control group(P<0.05).After 2 months of treatment,the gastrin(GAS)and motilin(MTL)in the two groups were lower than those before treatment,the gastric semi emptying time and gastric emptying time were shorter than those before treatment,and the levels of GAS and MTL in the experimental group were lower than those in the control group,and the gastric semi emptying time and gastric emptying time were shorter than those in the control group(P<0.05).After 2 months of treatment,the levels of interleukin-17(IL-17),interleukin-23(IL-23)and tumor necrosis factor-α(TNF-α)in the experimental group were lower than those in the control group(P<0.05).The total incidence of adverse reactions in the experimental group was higher than that in the control group,but there was no significant difference between the two groups.Conclusion The rabeprazole combined with mosapride in the treatment of RE can effectively improve the treatment effect,reduce the levels of GAS and MTL,accelerate the process of gastric emptying,reduce the level of inflammatory factors,and will not increase the occurrence of adverse reactions,it is worthy of clinical application.